

Is Ipratropium still in shortage in 2026? Get the latest update on supply, pricing, alternatives, and how to find Ipratropium in stock near you.
If you or a loved one depends on Ipratropium to manage COPD, asthma, or a chronic runny nose, you've probably noticed something troubling: it's not always easy to find at the pharmacy. Ipratropium supply issues have been making headlines since 2023, and patients are still feeling the effects in 2026.
In this update, we'll cover the current state of the Ipratropium shortage, why it's happening, what it costs, and — most importantly — how you can find it or find an alternative.
The short answer: it depends on the formulation.
The Ipratropium shortage situation in 2026 varies by product type:
For the most up-to-date availability information, check Medfinder to see which pharmacies near you have Ipratropium in stock right now.
Several factors have contributed to the ongoing supply challenges:
In 2023, Cipla USA discontinued their Albuterol/Ipratropium combination inhalation solution, removing a key supplier from the market. With fewer manufacturers producing these products, any production delay at one facility has a bigger impact on overall supply.
Boehringer Ingelheim, the maker of brand-name Atrovent HFA, has also experienced periodic manufacturing constraints.
Respiratory medications see sharp demand increases during fall and winter. Flu, COVID-19, RSV, and cold seasons drive up hospital and pharmacy use of nebulized Ipratropium, sometimes outpacing supply.
Metered-dose inhalers are technically complex to manufacture. Unlike simple tablets or solutions, they require specialized propellants, valves, and canisters. This makes it harder for new generic manufacturers to enter the market quickly.
For a deeper look at these factors, read our post on why Ipratropium is so hard to find.
Cost is another concern, especially if a shortage forces you to fill at a different pharmacy or pay out of pocket. Here's a snapshot of current pricing:
The generic versions are very affordable with coupon cards from services like SingleCare or GoodRx. The brand-name inhaler is significantly more expensive, but Boehringer Ingelheim now offers a $35/month cap on out-of-pocket costs for eligible commercially insured patients.
For more cost-saving strategies, see our detailed guide on how to save money on Ipratropium.
If you can't find Ipratropium, several alternatives in the same drug class may work for you:
These are long-acting medications, so they work differently than short-acting Ipratropium. Your doctor will need to evaluate whether a switch is appropriate. Read our full comparison in alternatives to Ipratropium.
Here's a step-by-step approach to tracking down your medication:
For more detailed strategies, check out our guide on how to find Ipratropium in stock near you.
The Ipratropium shortage in 2026 is real — but it's not uniform across all formulations or all parts of the country. Generic nebulizer solutions and nasal sprays are generally more available than the brand-name inhaler. Prices remain affordable for generics (as low as $14 with a coupon), and alternatives exist for patients who can't find their usual formulation.
The most important thing you can do is stay proactive: use Medfinder to check availability, talk to your doctor about backup options, and never wait until you're completely out to start looking for a refill.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.